Gedeon Richter raised its full-year 2026 revenue and profit guidance after reporting third-quarter and first nine-month results on Tuesday, according to Investing.com.

The Budapest-based pharmaceutical company said its pharma revenues grew 11.7% at constant exchange rates in the first nine months. Reported pharma revenues rose 2.6% to HUF 686.5bn. The company said currency movements cut about 9 percentage points from reported growth.

Clean EBIT for pharma rose 25% at constant exchange rates over the nine months. Reported Clean EBIT increased 8% to HUF 229.9bn. The company attributed the gains to its BIO division approaching breakeven, continued strength in cariprazine, and lower operating expenses from efficiency initiatives.

Net profit attributable to owners reached HUF 174.9bn, up 7.1% from a year earlier. Free cash flow before mergers and acquisitions rose 12% to a record HUF 223bn.

By segment, CNS revenues grew 19% at constant exchange rates, driven by Vraylar sales. AbbVie reported Vraylar sales of $3.04bn, up 17%. Reagila sales rose 37% at constant exchange rates. Women's Healthcare sales grew 11% at constant exchange rates over the nine months, accelerating to 19% in the third quarter, with Ryeqo, Lenzetto and Drovelis as the main contributors. BIO revenues increased 35% at constant exchange rates, supported by biosimilars and CDMO revenues.

Gedeon Richter now expects 2026 revenue growth above 10% at constant exchange rates. It raised its Clean EBIT guidance to high-teens growth.